---
document_datetime: 2025-12-02 04:58:53
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/beyfortus.html
document_name: beyfortus.html
version: success
processing_time: 0.1301518
conversion_datetime: 2025-12-28 04:01:14.28938
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Beyfortus

[RSS](/en/individual-human-medicine.xml/67615)

##### Authorised

This medicine is authorised for use in the European Union

nirsevimab Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Beyfortus](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-77352)
- [More information on Beyfortus](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Beyfortus is a medicine used to prevent serious lower respiratory tract (lung) disease caused by respiratory syncytial virus (RSV) in newborns and children during their first RSV season.

Beyfortus contains the active substance nirsevimab.

Expand section

Collapse section

## How is Beyfortus used?

The medicine can only be obtained with a prescription.

Beyfortus is given as a single injection into the thigh muscle. It is given once before the RSV season starts or at birth for infants born during the RSV season. The recommended dose is 50 mg for children weighing less than 5 kg and 100 mg for children weighing 5 kg or more.

For more information about using Beyfortus, see the package leaflet or contact your healthcare provider.

## How does Beyfortus work?

The active substance in Beyfortus, nirsevimab, is a monoclonal antibody. A monoclonal antibody is a type of protein that has been designed to recognise and attach to a specific structure (called an antigen). Nirsevimab attaches to a protein called 'F protein' on the surface of RSV. When nirsevimab is attached to this protein, the virus becomes unable to enter the body's cells, especially those in the lungs. This helps to prevent RSV infection.

## What benefits of Beyfortus have been shown in studies?

Beyfortus was shown to be effective at reducing lower respiratory tract disease caused by RSV in three main studies.

One study compared Beyfortus with placebo (a dummy treatment) in 1,490 healthy children born prematurely and at term (at 35 weeks gestation or more). After receiving Beyfortus during their first RSV season, 1.2% of children (12 out of 994) developed RSV-induced lung disease that required medical attention compared with 5% 1 (25 out of 496) in the placebo group.

Similar results were seen in a second study comparing Beyfortus with placebo in 1,453 children born five or more weeks prematurely (between 29 and 35 weeks gestation). After receiving Beyfortus during their first RSV season, 2.6% of children (25 out of 969) developed RSV-induced lung disease that required medical attention compared with 9.5% (46 out of 484) in the placebo group.

A third study compared Beyfortus with palivizumab (another medicine to prevent RSV-induced lung disease) in children who were either born prematurely, or born at full term but had heart or lung disease which put them at risk of RSV-induced lung disease. After receiving Beyfortus, 4 children (out of 616) developed RSV-induced lung disease that required medical attention compared with 3 children (out of 309) in the group who had palivizumab.

1 Correction of percentage in section \"what benefits of Beyfortus have been shown in studies?\": 2.6% has been amended to 5% (25 out of 496)

## What are the risks associated with Beyfortus?

The most common side effects with Beyfortus (which may affect up to 1 in 100 people) are rash occurring within 14 days after injection, and fever and injection site reactions occurring within 7 days after injection.

For the full list of side effects and restrictions with Beyfortus, see the package leaflet.

## Why is Beyfortus authorised in the EU?

Beyfortus was shown to be effective at preventing RSV-induced lung disease that required medical attention. In terms of safety, its side effects are considered manageable and in line with what can be expected of this class of medicines. The European Medicines Agency decided that Beyfortus's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Beyfortus?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Beyfortus have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Beyfortus are continuously monitored. Suspected side effects reported with Beyfortus are carefully evaluated and any necessary action taken to protect patients.

## Other information about Beyfortus

Beyfortus received a marketing authorisation valid throughout the EU on 31 October 2022.

Beyfortus : EPAR - Medicine Overview

Reference Number: EMA/776857/2022

English (EN) (100.35 KB - PDF)

**First published:** 15/11/2022

**Last updated:** 04/09/2024

[View](/en/documents/overview/beyfortus-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-959)

български (BG) (179.21 KB - PDF)

**First published:**

04/09/2024

[View](/bg/documents/overview/beyfortus-epar-medicine-overview_bg.pdf)

español (ES) (153.37 KB - PDF)

**First published:**

04/09/2024

[View](/es/documents/overview/beyfortus-epar-medicine-overview_es.pdf)

čeština (CS) (177.56 KB - PDF)

**First published:**

04/09/2024

[View](/cs/documents/overview/beyfortus-epar-medicine-overview_cs.pdf)

dansk (DA) (152.68 KB - PDF)

**First published:**

04/09/2024

[View](/da/documents/overview/beyfortus-epar-medicine-overview_da.pdf)

Deutsch (DE) (156.84 KB - PDF)

**First published:**

04/09/2024

[View](/de/documents/overview/beyfortus-epar-medicine-overview_de.pdf)

eesti keel (ET) (151.55 KB - PDF)

**First published:**

04/09/2024

[View](/et/documents/overview/beyfortus-epar-medicine-overview_et.pdf)

ελληνικά (EL) (177.42 KB - PDF)

**First published:**

04/09/2024

[View](/el/documents/overview/beyfortus-epar-medicine-overview_el.pdf)

français (FR) (155.63 KB - PDF)

**First published:**

04/09/2024

[View](/fr/documents/overview/beyfortus-epar-medicine-overview_fr.pdf)

hrvatski (HR) (176.71 KB - PDF)

**First published:**

04/09/2024

[View](/hr/documents/overview/beyfortus-epar-medicine-overview_hr.pdf)

italiano (IT) (152.92 KB - PDF)

**First published:**

04/09/2024

[View](/it/documents/overview/beyfortus-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (186.03 KB - PDF)

**First published:**

04/09/2024

[View](/lv/documents/overview/beyfortus-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (175.73 KB - PDF)

**First published:**

04/09/2024

[View](/lt/documents/overview/beyfortus-epar-medicine-overview_lt.pdf)

magyar (HU) (177.1 KB - PDF)

**First published:**

04/09/2024

[View](/hu/documents/overview/beyfortus-epar-medicine-overview_hu.pdf)

Malti (MT) (178.73 KB - PDF)

**First published:**

04/09/2024

[View](/mt/documents/overview/beyfortus-epar-medicine-overview_mt.pdf)

Nederlands (NL) (153.78 KB - PDF)

**First published:**

04/09/2024

[View](/nl/documents/overview/beyfortus-epar-medicine-overview_nl.pdf)

polski (PL) (178.22 KB - PDF)

**First published:**

04/09/2024

[View](/pl/documents/overview/beyfortus-epar-medicine-overview_pl.pdf)

português (PT) (154.69 KB - PDF)

**First published:**

04/09/2024

[View](/pt/documents/overview/beyfortus-epar-medicine-overview_pt.pdf)

română (RO) (174.73 KB - PDF)

**First published:**

04/09/2024

[View](/ro/documents/overview/beyfortus-epar-medicine-overview_ro.pdf)

slovenčina (SK) (175 KB - PDF)

**First published:**

04/09/2024

[View](/sk/documents/overview/beyfortus-epar-medicine-overview_sk.pdf)

slovenščina (SL) (174.51 KB - PDF)

**First published:**

04/09/2024

[View](/sl/documents/overview/beyfortus-epar-medicine-overview_sl.pdf)

Suomi (FI) (151.61 KB - PDF)

**First published:**

04/09/2024

[View](/fi/documents/overview/beyfortus-epar-medicine-overview_fi.pdf)

svenska (SV) (151.79 KB - PDF)

**First published:**

04/09/2024

[View](/sv/documents/overview/beyfortus-epar-medicine-overview_sv.pdf)

Beyfortus : EPAR - Risk management plan

English (EN) (743.44 KB - PDF)

**First published:** 15/11/2022

**Last updated:** 07/10/2024

[View](/en/documents/rmp/beyfortus-epar-risk-management-plan_en.pdf)

## Product information

Beyfortus : EPAR - Product Information

English (EN) (374.97 KB - PDF)

**First published:** 15/11/2022

**Last updated:** 17/06/2025

[View](/en/documents/product-information/beyfortus-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-6)

български (BG) (521.32 KB - PDF)

**First published:**

15/11/2022

**Last updated:**

17/06/2025

[View](/bg/documents/product-information/beyfortus-epar-product-information_bg.pdf)

español (ES) (522.64 KB - PDF)

**First published:**

15/11/2022

**Last updated:**

17/06/2025

[View](/es/documents/product-information/beyfortus-epar-product-information_es.pdf)

čeština (CS) (724.63 KB - PDF)

**First published:**

15/11/2022

**Last updated:**

17/06/2025

[View](/cs/documents/product-information/beyfortus-epar-product-information_cs.pdf)

dansk (DA) (472.66 KB - PDF)

**First published:**

15/11/2022

**Last updated:**

17/06/2025

[View](/da/documents/product-information/beyfortus-epar-product-information_da.pdf)

Deutsch (DE) (654.91 KB - PDF)

**First published:**

15/11/2022

**Last updated:**

17/06/2025

[View](/de/documents/product-information/beyfortus-epar-product-information_de.pdf)

eesti keel (ET) (329.72 KB - PDF)

**First published:**

15/11/2022

**Last updated:**

17/06/2025

[View](/et/documents/product-information/beyfortus-epar-product-information_et.pdf)

ελληνικά (EL) (579.97 KB - PDF)

**First published:**

15/11/2022

**Last updated:**

17/06/2025

[View](/el/documents/product-information/beyfortus-epar-product-information_el.pdf)

français (FR) (650.09 KB - PDF)

**First published:**

15/11/2022

**Last updated:**

17/06/2025

[View](/fr/documents/product-information/beyfortus-epar-product-information_fr.pdf)

hrvatski (HR) (429.68 KB - PDF)

**First published:**

15/11/2022

**Last updated:**

17/06/2025

[View](/hr/documents/product-information/beyfortus-epar-product-information_hr.pdf)

íslenska (IS) (499.63 KB - PDF)

**First published:**

15/11/2022

**Last updated:**

17/06/2025

[View](/is/documents/product-information/beyfortus-epar-product-information_is.pdf)

italiano (IT) (480.66 KB - PDF)

**First published:**

15/11/2022

**Last updated:**

17/06/2025

[View](/it/documents/product-information/beyfortus-epar-product-information_it.pdf)

latviešu valoda (LV) (633.98 KB - PDF)

**First published:**

15/11/2022

**Last updated:**

17/06/2025

[View](/lv/documents/product-information/beyfortus-epar-product-information_lv.pdf)

lietuvių kalba (LT) (429.38 KB - PDF)

**First published:**

15/11/2022

**Last updated:**

17/06/2025

[View](/lt/documents/product-information/beyfortus-epar-product-information_lt.pdf)

magyar (HU) (396.86 KB - PDF)

**First published:**

15/11/2022

**Last updated:**

17/06/2025

[View](/hu/documents/product-information/beyfortus-epar-product-information_hu.pdf)

Malti (MT) (675.39 KB - PDF)

**First published:**

15/11/2022

**Last updated:**

17/06/2025

[View](/mt/documents/product-information/beyfortus-epar-product-information_mt.pdf)

Nederlands (NL) (474.94 KB - PDF)

**First published:**

15/11/2022

**Last updated:**

17/06/2025

[View](/nl/documents/product-information/beyfortus-epar-product-information_nl.pdf)

norsk (NO) (539.26 KB - PDF)

**First published:**

15/11/2022

**Last updated:**

17/06/2025

[View](/no/documents/product-information/beyfortus-epar-product-information_no.pdf)

polski (PL) (543.63 KB - PDF)

**First published:**

15/11/2022

**Last updated:**

17/06/2025

[View](/pl/documents/product-information/beyfortus-epar-product-information_pl.pdf)

português (PT) (423.5 KB - PDF)

**First published:**

15/11/2022

**Last updated:**

17/06/2025

[View](/pt/documents/product-information/beyfortus-epar-product-information_pt.pdf)

română (RO) (606.16 KB - PDF)

**First published:**

15/11/2022

**Last updated:**

17/06/2025

[View](/ro/documents/product-information/beyfortus-epar-product-information_ro.pdf)

slovenčina (SK) (563.39 KB - PDF)

**First published:**

15/11/2022

**Last updated:**

17/06/2025

[View](/sk/documents/product-information/beyfortus-epar-product-information_sk.pdf)

slovenščina (SL) (515.82 KB - PDF)

**First published:**

15/11/2022

**Last updated:**

17/06/2025

[View](/sl/documents/product-information/beyfortus-epar-product-information_sl.pdf)

Suomi (FI) (653.22 KB - PDF)

**First published:**

15/11/2022

**Last updated:**

17/06/2025

[View](/fi/documents/product-information/beyfortus-epar-product-information_fi.pdf)

svenska (SV) (618.03 KB - PDF)

**First published:**

15/11/2022

**Last updated:**

17/06/2025

[View](/sv/documents/product-information/beyfortus-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0028 25/04/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Beyfortus : EPAR - All authorised presentations

English (EN) (25.07 KB - PDF)

**First published:** 15/11/2022

[View](/en/documents/all-authorised-presentations/beyfortus-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-729)

български (BG) (30.06 KB - PDF)

**First published:**

15/11/2022

[View](/bg/documents/all-authorised-presentations/beyfortus-epar-all-authorised-presentations_bg.pdf)

español (ES) (24.98 KB - PDF)

**First published:**

15/11/2022

[View](/es/documents/all-authorised-presentations/beyfortus-epar-all-authorised-presentations_es.pdf)

čeština (CS) (26.64 KB - PDF)

**First published:**

15/11/2022

[View](/cs/documents/all-authorised-presentations/beyfortus-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (26.34 KB - PDF)

**First published:**

15/11/2022

[View](/da/documents/all-authorised-presentations/beyfortus-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (28.87 KB - PDF)

**First published:**

15/11/2022

[View](/de/documents/all-authorised-presentations/beyfortus-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (23.53 KB - PDF)

**First published:**

15/11/2022

[View](/et/documents/all-authorised-presentations/beyfortus-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (29.53 KB - PDF)

**First published:**

15/11/2022

[View](/el/documents/all-authorised-presentations/beyfortus-epar-all-authorised-presentations_el.pdf)

français (FR) (25.88 KB - PDF)

**First published:**

15/11/2022

[View](/fr/documents/all-authorised-presentations/beyfortus-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (27.38 KB - PDF)

**First published:**

15/11/2022

[View](/hr/documents/all-authorised-presentations/beyfortus-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (26.77 KB - PDF)

**First published:**

15/11/2022

[View](/is/documents/all-authorised-presentations/beyfortus-epar-all-authorised-presentations_is.pdf)

italiano (IT) (24.89 KB - PDF)

**First published:**

15/11/2022

[View](/it/documents/all-authorised-presentations/beyfortus-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (25.42 KB - PDF)

**First published:**

15/11/2022

[View](/lv/documents/all-authorised-presentations/beyfortus-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (25.44 KB - PDF)

**First published:**

15/11/2022

[View](/lt/documents/all-authorised-presentations/beyfortus-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (28.59 KB - PDF)

**First published:**

15/11/2022

[View](/hu/documents/all-authorised-presentations/beyfortus-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (28.54 KB - PDF)

**First published:**

15/11/2022

[View](/mt/documents/all-authorised-presentations/beyfortus-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (24.65 KB - PDF)

**First published:**

15/11/2022

[View](/nl/documents/all-authorised-presentations/beyfortus-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (26.31 KB - PDF)

**First published:**

15/11/2022

[View](/no/documents/all-authorised-presentations/beyfortus-epar-all-authorised-presentations_no.pdf)

polski (PL) (28.38 KB - PDF)

**First published:**

15/11/2022

[View](/pl/documents/all-authorised-presentations/beyfortus-epar-all-authorised-presentations_pl.pdf)

português (PT) (25.47 KB - PDF)

**First published:**

15/11/2022

[View](/pt/documents/all-authorised-presentations/beyfortus-epar-all-authorised-presentations_pt.pdf)

română (RO) (27.14 KB - PDF)

**First published:**

15/11/2022

[View](/ro/documents/all-authorised-presentations/beyfortus-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (25.32 KB - PDF)

**First published:**

15/11/2022

[View](/sk/documents/all-authorised-presentations/beyfortus-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (24.16 KB - PDF)

**First published:**

15/11/2022

[View](/sl/documents/all-authorised-presentations/beyfortus-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (23.86 KB - PDF)

**First published:**

15/11/2022

[View](/fi/documents/all-authorised-presentations/beyfortus-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (25.14 KB - PDF)

**First published:**

15/11/2022

[View](/sv/documents/all-authorised-presentations/beyfortus-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Beyfortus Active substance nirsevimab International non-proprietary name (INN) or common name nirsevimab Anatomical therapeutic chemical (ATC) code J06BD08

### Pharmacotherapeutic group

Immune sera and immunoglobulins

### Therapeutic indication

Beyfortus is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in: i.        Neonates and infants during their first RSV season. ii.        Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season (see section 5.1). Beyfortus should be used in accordance with official recommendations.

Beyfortus is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in: i.          Neonates and infants during their first RSV season. ii.         Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season (see section 5.1). Beyfortus should be used in accordance with official recommendations.

## Authorisation details

EMA product number EMEA/H/C/005304

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

PRIME: priority medicine

This medicine was granted entry to the EMA Priority Medicines (PRIME) scheme during its development. PRIME is a scheme launched by EMA to enhance support for the development of medicines that target an unmet medical need. This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach patients earlier. For more information, see [PRIME: priority medicines](/node/69853) .

Marketing authorisation holder

Sanofi Winthrop Industrie

82 Avenue Raspail

Opinion adopted 15/09/2022 Marketing authorisation issued 31/10/2022 Revision 12

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Beyfortus : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (130.38 KB - PDF)

**First published:** 14/02/2025

**Last updated:** 02/05/2025

[View](/en/documents/procedural-steps-after/beyfortus-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Beyfortus : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (180.41 KB - PDF)

**First published:** 21/03/2023

**Last updated:** 24/06/2025

[View](/en/documents/procedural-steps-after/beyfortus-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Beyfortus-H-C-005304-II-0005 : EPAR - Assessment report - Variation

Reference Number: EMA/355992/2024

English (EN) (7.86 MB - PDF)

**First published:** 24/09/2024

[View](/en/documents/variation-report/beyfortus-h-c-005304-ii-0005-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Beyfortus (II-05)

Adopted

Reference Number: EMA/CHMP/37430/2024

English (EN) (209.76 KB - PDF)

**First published:** 28/06/2024

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-beyfortus-ii-05_en.pdf)

Beyfortus : EPAR - Statement indicating compliance with the agreed completed paediatric investigation plan

Reference Number: EMA/182502/2024

English (EN) (92.88 KB - PDF)

**First published:** 05/06/2024

[View](/en/documents/pip-compliance/beyfortus-epar-statement-indicating-compliance-agreed-completed-paediatric-investigation-plan_en.pdf)

Beyfortus-H-C-005304-P46-006 : EPAR - Assessment Report

English (EN) (881.13 KB - PDF)

**First published:** 15/01/2024

[View](/en/documents/variation-report/beyfortus-h-c-005304-p46-006-epar-assessment-report_en.pdf)

## Initial marketing authorisation documents

Beyfortus : EPAR - Public assessment report

Adopted

Reference Number: EMA/786523/2022

English (EN) (7.24 MB - PDF)

**First published:** 15/11/2022

[View](/en/documents/assessment-report/beyfortus-epar-public-assessment-report_en.pdf)

#### News on Beyfortus

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2024) 28/06/2024

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 January 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-january-2024) 26/01/2024

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-september-2022) 16/09/2022

[New medicine to protect babies and infants from respiratory syncytial virus (RSV) infection](/en/news/new-medicine-protect-babies-and-infants-respiratory-syncytial-virus-rsv-infection) 16/09/2022

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Beyfortus : EPAR - Product information - tracked changes

English (EN) (196.38 KB - DOCX)

**First published:** 17/06/2025

[View](/en/documents/product-information-tracked-changes/beyfortus-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-880)

български (BG) (186.88 KB - DOCX)

**First published:**

17/06/2025

[View](/bg/documents/product-information-tracked-changes/beyfortus-epar-product-information-tracked-changes_bg.docx)

español (ES) (186.62 KB - DOCX)

**First published:**

17/06/2025

[View](/es/documents/product-information-tracked-changes/beyfortus-epar-product-information-tracked-changes_es.docx)

čeština (CS) (193.26 KB - DOCX)

**First published:**

17/06/2025

[View](/cs/documents/product-information-tracked-changes/beyfortus-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (236.73 KB - DOCX)

**First published:**

17/06/2025

[View](/da/documents/product-information-tracked-changes/beyfortus-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (230.53 KB - DOCX)

**First published:**

17/06/2025

[View](/de/documents/product-information-tracked-changes/beyfortus-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (193.54 KB - DOCX)

**First published:**

17/06/2025

[View](/et/documents/product-information-tracked-changes/beyfortus-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (186.83 KB - DOCX)

**First published:**

17/06/2025

[View](/el/documents/product-information-tracked-changes/beyfortus-epar-product-information-tracked-changes_el.docx)

français (FR) (351.3 KB - DOCX)

**First published:**

17/06/2025

[View](/fr/documents/product-information-tracked-changes/beyfortus-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (205.27 KB - DOCX)

**First published:**

17/06/2025

[View](/hr/documents/product-information-tracked-changes/beyfortus-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (253.03 KB - DOCX)

**First published:**

17/06/2025

[View](/is/documents/product-information-tracked-changes/beyfortus-epar-product-information-tracked-changes_is.docx)

italiano (IT) (202.59 KB - DOCX)

**First published:**

17/06/2025

[View](/it/documents/product-information-tracked-changes/beyfortus-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (193.74 KB - DOCX)

**First published:**

17/06/2025

[View](/lv/documents/product-information-tracked-changes/beyfortus-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (264 KB - DOCX)

**First published:**

17/06/2025

[View](/lt/documents/product-information-tracked-changes/beyfortus-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (205.38 KB - DOCX)

**First published:**

17/06/2025

[View](/hu/documents/product-information-tracked-changes/beyfortus-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (367.88 KB - DOCX)

**First published:**

17/06/2025

[View](/mt/documents/product-information-tracked-changes/beyfortus-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (175.29 KB - DOCX)

**First published:**

17/06/2025

[View](/nl/documents/product-information-tracked-changes/beyfortus-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (372.53 KB - DOCX)

**First published:**

17/06/2025

[View](/no/documents/product-information-tracked-changes/beyfortus-epar-product-information-tracked-changes_no.docx)

polski (PL) (195.56 KB - DOCX)

**First published:**

17/06/2025

[View](/pl/documents/product-information-tracked-changes/beyfortus-epar-product-information-tracked-changes_pl.docx)

português (PT) (159.24 KB - DOCX)

**First published:**

17/06/2025

[View](/pt/documents/product-information-tracked-changes/beyfortus-epar-product-information-tracked-changes_pt.docx)

română (RO) (188.85 KB - DOCX)

**First published:**

17/06/2025

[View](/ro/documents/product-information-tracked-changes/beyfortus-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (250.39 KB - DOCX)

**First published:**

17/06/2025

[View](/sk/documents/product-information-tracked-changes/beyfortus-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (168.47 KB - DOCX)

**First published:**

17/06/2025

[View](/sl/documents/product-information-tracked-changes/beyfortus-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (171.78 KB - DOCX)

**First published:**

17/06/2025

[View](/fi/documents/product-information-tracked-changes/beyfortus-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (170.29 KB - DOCX)

**First published:**

17/06/2025

[View](/sv/documents/product-information-tracked-changes/beyfortus-epar-product-information-tracked-changes_sv.docx)

#### More information on Beyfortus

- [EMEA-001784-PIP01-15-M04 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001784-pip01-15-m04)

**This page was last updated on** 24/06/2025

## Share this page

[Back to top](#main-content)